Gilead Sciences stock: Jefferies lifts its target to USD 185 for Gilead Sciences stock
Published on 10/23/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target raised
- Jefferies lifted its Gilead Sciences target to USD 185.00 from USD 184.00 on October 23, 2026.
- Gilead agreed to acquire PepStar Therapeutics' drug candidate for USD 1.28 billion in cash.
- Gilead Sciences stock costs EUR 139.37 at Lang & Schwarz on October 23, 2026 at 4:31 p.m. CEST, 0.31 percent above the Xetra close of October 22, 2026.
- Gilead is scheduled to report quarterly results on October 29, 2026.
On October 23, 2026, Jefferies lifted its Gilead Sciences target to USD 185.00 from USD 184.00 while maintaining a Buy rating, as Investing.com reported. The target stands 18.72 percent above Gilead's USD 155.83 Nasdaq price. At Lang & Schwarz, Gilead Sciences traded at EUR 139.37 on October 23, 2026 at 4:31 p.m. CEST, up 0.31 percent versus the Xetra close of October 22, 2026.
Acquisition adds an early pipeline asset
Jefferies linked its target update to Gilead's agreement to acquire PepStar Therapeutics' Phase 1 oral anti-IL-23 candidate HCXT-2001 for USD 1.275 billion in cash. The deal gives Gilead a drug candidate that could be combined with emvistegrast in ulcerative colitis, although HCXT-2001 remains in early clinical development, according to Investing.com.
Stock sits below its yearly high
Gilead's Nasdaq price was USD 155.83 on October 23, 2026 at 10:36 a.m. ET, placing it 2.92 percent below the USD 160.51 52-week high and above the USD 114.02 low. The stock had gained 30.00 percent year to date, while the latest reported volume was 1,175,725 shares.
Results date and valuation
Gilead's second-quarter revenue was USD 7.80 billion, up 10.60 percent from the prior-year quarter and above the USD 7.40 billion consensus estimate, according to MarketBeat. The company is scheduled to release its next quarterly results on October 29, 2026, according to Investing.com.
Comparison with peers
Gilead Sciences: up 0.31 percent versus the Xetra close, P/E minus 58.44, market capitalization USD 193.2 billion.
AbbVie (NYSE, USD): down 0.77 percent, P/E 79.78, market capitalization USD 500.1 billion.
Amgen (Nasdaq, USD): down 1.51 percent, P/E 27.39, market capitalization USD 238.2 billion.
Target rises while price stays measured
The latest target increase gives investors a higher valuation marker, while the euro quotation remains only 0.31 percent above the October 22 Xetra close. Gilead's next earnings date will provide the next scheduled test of the revenue trajectory and the acquisition-led pipeline narrative.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences market data
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 23, 2026, 4:31 p.m. CEST): EUR 139.37
- Change versus Xetra close: plus 0.31 percent
- Xetra close (October 22, 2026): EUR 138.94
- Market capitalization: USD 193.2 billion (as of October 23, 2026)
- 52-week range: USD 114.02-160.51 (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
Market context: Market report Nasdaq Composite.
